Sigilon Therapeutics Statistics Share Statistics Sigilon Therapeutics has 2.5M
shares outstanding. The number of shares has increased by 2.94%
in one year.
Shares Outstanding 2.5M Shares Change (YoY) 2.94% Shares Change (QoQ) 0.18% Owned by Institutions (%) n/a Shares Floating 1.49M Failed to Deliver (FTD) Shares 27 FTD / Avg. Volume 0.02%
Short Selling Information The latest short interest is 8.23K, so 0.33% of the outstanding
shares have been sold short.
Short Interest 8.23K Short % of Shares Out 0.33% Short % of Float 0.48% Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -3.39 and the forward
PE ratio is null.
Sigilon Therapeutics's PEG ratio is
0.04.
PE Ratio -3.39 Forward PE n/a PS Ratio 11.39 Forward PS n/a PB Ratio 3.77 P/FCF Ratio -2.83 PEG Ratio 0.04
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Sigilon Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 2.4,
with a Debt / Equity ratio of 0.72.
Current Ratio 2.4 Quick Ratio 2.39 Debt / Equity 0.72 Debt / EBITDA -0.68 Debt / FCF -0.54 Interest Coverage -19.07
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $208.77K Profits Per Employee $-700.9K Employee Count 62 Asset Turnover 0.15 Inventory Turnover n/a
Taxes Income Tax -105K Effective Tax Rate 0.24%
Stock Price Statistics The stock price has increased by 0% in the
last 52 weeks. The beta is 4.11, so Sigilon Therapeutics's
price volatility has been higher than the market average.
Beta 4.11 52-Week Price Change n/a 50-Day Moving Average 16.97 200-Day Moving Average 10.29 Relative Strength Index (RSI) 71.26 Average Volume (20 Days) 120,683
Income Statement In the last 12 months, Sigilon Therapeutics had revenue of 12.94M
and earned -43.46M
in profits. Earnings per share was -1.34.
Revenue 12.94M Gross Profit 12.94M Operating Income -43.67M Net Income -43.46M EBITDA -41.27M EBIT -41.27M Earnings Per Share (EPS) -1.34
Full Income Statement Balance Sheet The company has 42.07M in cash and 28.06M in
debt, giving a net cash position of 14.01M.
Cash & Cash Equivalents 42.07M Total Debt 28.06M Net Cash 14.01M Retained Earnings -256.8M Total Assets 55.56M Working Capital 19.62M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -51.47M
and capital expenditures -537K, giving a free cash flow of -52.01M.
Operating Cash Flow -51.47M Capital Expenditures -537K Free Cash Flow -52.01M FCF Per Share -1.6
Full Cash Flow Statement Margins Gross margin is 100%, with operating and profit margins of -337.35% and -335.72%.
Gross Margin 100% Operating Margin -337.35% Pretax Margin -336.53% Profit Margin -335.72% EBITDA Margin -318.84% EBIT Margin -337.35% FCF Margin -401.82%
Dividends & Yields SGTX does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for SGTX.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on May 23, 2023. It was a
backward
split with a ratio of 1:13.
Last Split Date May 23, 2023 Split Type backward Split Ratio 1:13
Scores Altman Z-Score -6.71 Piotroski F-Score 2
